Prevention of Delirium After Bone Marrow Transplantation
Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Sponsor: American Cancer Society, Inc.
Terminated
Low incidence of delirium.
Other terminated trials from American Cancer Society, Inc.
- Colorectal Cancer · Jan 2025
- Smoking Cessation · Phase NA · Mar 2020
- Adherence, Medication · Phase PHASE2 · Mar 2020
- Non-small Cell Lung Cancer · Phase PHASE2 · Sep 2019
- Recurrent Plasma Cell Myeloma · Phase PHASE2 · Nov 2018
More terminations from American Cancer Society, Inc.
Other Delirium trials with similar outcome
Listed as NCT01700816, this NA trial focuses on Delirium and remains terminated or withdrawn. Sponsored by American Cancer Society, Inc., it has been updated 8 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Jan 2023 — Jul 2024 [monthly]
Terminated NA
-
Dec 2022 — Jan 2023 [monthly]
Terminated NA
-
Jan 2021 — Dec 2022 [monthly]
Terminated NA
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated NA
-
Aug 2017 — Jun 2018 [monthly]
Terminated NA
Status: Unknown Status → Terminated
-
Jan 2017 — Aug 2017 [monthly]
Unknown Status NA
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- American Cancer Society, Inc.
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .